AbCellera Biologics Inc Investor Event Transcript, Nov 16, 2026
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. said ABCL635 achieved twice the frequency and four to five times the severity efficacy of approved small molecules, with a clean safety profile supporting planned late-stage development. AI summary
Conference Transcript - ABCL 2026-11-16
Roger Song, Analyst — Jefferies
Welcome, everyone, to Jeffrey's 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst covering Simica Biotech in the U.S. It is my pleasure to have a five-step chat with Absalara. We have CEO Carl Hansen with me.
Carl Hansen, CEO
Great to be here. Thanks, Roger.
Roger Song, Analyst — Jefferies
Excellent. Okay, Carl, you know, a lot of excitement happened to your company, and then can you give us the state of the art of Accelera and why you are excited about the 2027 and beyond?
Carl Hansen, CEO
Sure. So first, thanks for having us. Just to set the stage, as Celera is a biotech company in Vancouver, we're focused on making antibody therapeutics. We spent the first 10 years of the company building a platform that we now think is best in the world, particularly for solving the really difficult challenges in antibody discovery. Good examples being antibodies that are functional against ion channels, against GPCRs, and increasingly some work in T-cell engagers. Much of that work was done through a partnership mode. We were essentially hired guns for biotech and big pharma. In 2023, we decided to switch gears. We started to ramp down that business and have been focused on our internal portfolio. And just over the last year, had our first two programs enter the clinic. One of them was an OX40 ligand antibody that we got sort of opportunistically. It's read out well, but we've decided to pause it based on the class. And the most exciting one is our lead asset, which is ABCL635. It's a first-in-class antibody antagonist of NK3R that is being developed for the non-hormonal treatment of hot flashes or vasomotor symptoms associated with both menopause and with androgen deprivation or hormone deprivation in cancer therapy. So we just had our phase two readout in August and Basically, the data blew the doors off, so we've got efficacy that is twice as good in frequency as the small molecules that are approved, four to five times as good in severity, a clean safety profile, and we are now getting ready to engage with the regulators and bring that into late-stage studies next year, and we think we've got something that can really redefine the treatment of hot flashes from a non-hormonal perspective.
Roger Song, Analyst — Jefferies
Great. Not many times we cannot really double or triple, quadruple the stand of care on efficacy. Okay, so that four-week data absolutely knocks people's socks off. And then you do have another data set coming early next year. So that is a 12-week following the single dose, and then the four weeks for the second dose, and then placebo crossover. So maybe for this one, on the single... Dose A in the 12-week. How should we think about that data? I know it's, you know, single dose and a washout, and then when we see the data, we'll be considered to be good and then supportive.
Carl Hansen, CEO
Sure. Thanks for asking. So it's, maybe I'll start just by describing the study because it does create some confusion. It's a little bit unusual the way it was set up. So what we did in phase two is a single dose, 600 milligrams given once, and that dose was intended to mimic what would be the steady state exposure or concentration of a once-monthly 300 milligram injection. And then we had a single four-week efficacy readout. So this is severity and frequency of hot flashes, and that's the data that we read out in August, and that is the only really important efficacy readout as part of this study. The study actually goes for 12 weeks, so the next eight weeks is about having a washout period. The antibody we've disclosed has a half-life of roughly 30 days, so we've got three total half-lives where the antibody is washing out, and over that period, because of the nature of this pathway, we have a very tight temporal correlation between efficacy and target engagement. So we're able to use the exposure response data on a patient-by-patient basis This is to build up a detailed model of exposure response for the target, and that is being brought forward to the FDA through a model-informed drug development program, which allows us to specify the Phase III doses based on that. So to sum it up, the four-week was the efficacy. The next eight-week is a washout. We haven't yet shown that data. We will be showing it early next year. And as you mentioned, in addition to that, we'll be adding to that data disclosure the open-label extension where both the placebo arm and the active arm get another dose, another 600-milligram dose, followed by four-week data. So in terms of what looks good, I mean, we would, you know, we anticipate and I think would be terrific to have data that's confirmatory of what we already saw at four weeks. So we're expecting the efficacy to wane up to 12 weeks, then we dose again. We'll get the first glimpse of two doses, which helps to inform on durability of response, which in this class has been very good, and also gives additional data to further de-risk anti-antibody responses, which we have not seen to date and we feel good about as well, as well as a first dose of the placebo arm, which is interesting because the placebo arm, there's quite a placebo response, which we attribute, which I attribute primarily to reversion to the mean. So after that is washed out, you'll get to dose it and see if that patient group goes to where it was before. In terms of positivity, we want to maintain a super clean safety signal. So we've seen no evidence of liver toxicity, which has been a problem for the small molecules. We think it's due to metabolism. We haven't seen a gastrointestinal safety signal, which has also been an issue with some of the small molecules. We want to keep that clean, and then we'd like to see efficacy that looks comparable to what it was before, and given the gap we have, we're optimistic that'll be the case.
Roger Song, Analyst — Jefferies
Excellent. So just on the single dose, that's a washout period. So any efficacy toward the later part, particularly for the 12 weeks, any efficacy should be good. So investors should not over-interpret if the efficacy goes down, even below the aural. That's still a very acceptable profile.
Carl Hansen, CEO
Yeah, but if it turned out that the efficacy reverted to zero over that period, it would still be fine because that's not the intended dosing schedule. I think given what we've already seen, like over the four weeks, we saw rapid response. We got already to better than orals or at least equal to orals in the first week, and it continued to get better through the four-week period. So I think it's unlikely it'll rebound completely, but we do expect a degradation, and we're waiting to see what that looks like.
Roger Song, Analyst — Jefferies
Got it. All right, that's very clear. And then on the four-week endpoint, you know, because you set a very high bar for yourself, right? It's not set by anybody. Not your competitor, not the stand-of-care, not the clinically meaningful. So what would be still very good? What scenario if the full week is lower than what you saw before? Because comparable is fantastic. The validation and reaffirmation, that's very good. But, you know, let's say 50% or 75% higher than the stand-up care, you'll be still very, very happy about that?
Carl Hansen, CEO
Yeah. So when we began the program, the TPP was to have equal efficacy to the approved small molecules, but better safety. So far, the safety looks great. And as I mentioned, the efficacy is much, much better. So, you know, that's allowed us to readjust our expectations. I think, you know, without specifically answering your question, any efficacy data where you can look across the room at a graph and know that it's much better than the small molecules, I think still is above the bar. So maybe that's 50% better, maybe 75% better. One of the things that I think is very exciting about the data that has not been seen before for non-hormonal treatments is after a single dose at four weeks, 37% of women that started at a baseline of 10 moderate to severe VMS episodes per day went to zero. So there was complete resolution in 37% of women, and I think 60% of women had a 90% resolution or better. So these are efficacy numbers that vastly exceed not just other NK3R antagonists, but also, you know, other treatments, SSRIs, SNRIs, gabapentin, and stand at least equal, if not better, to hormonal treatments. And so, you know, we're very excited by that. And so in terms of, you know, preserving that, one of the things that we're looking at that others have not looked at is what is the level of, you know, not to say cure, but let's call it complete resolution of the problematic symptoms, because that is a very important differentiator for the product. Got it.
Roger Song, Analyst — Jefferies
Okay, and then, you know, because it's a second dose for the 365, and then do you expect that we'll have a little bit even better efficacy, you know, based on your PK accumulation exposure level?
Carl Hansen, CEO
Yeah, so for the active group that gets the OLE, there will be some accumulation. As I mentioned, the half-life is about a month, so we'll have three half-lives, so an eight-fold reduction. So you have a little bit of accumulation. You know, from first principles, I wouldn't think that that's going to be too important, but we'll see what the data shows.
Analyst
Is there any potential with this extension, with this 12-week data, that there could be a path to...
Carl Hansen, CEO
Yeah, so when we get the data, we'll... We'll inform the dose. I think right now, you know, the TPP, which was a once-monthly maintenance dose in a single shot, which is 300 milligrams because we're formulated at 150, is in the bank. So I think we're going to have that. There's an upside that could either be a lower dose on a monthly basis or it could be a less frequent dosing interval. At this point, I think it's unlikely you'd get to three months, but you might want to push it a bit. And since we brought it up, at the last earnings call, we also disclosed that we've brought a second candidate, which is a half-life extended version of baby sale 635 or an analog of it. That's one that we think would be able to achieve at least a once-quarterly dosing. And we see that as important both to make sure that we don't have other companies quickly following this insight And also because in the future, we imagine this could be a very high-volume product, and the cost of goods could be important for supply and also for pricing flexibility, particularly if we go to a commercial model that is not directly to prescribers but also more DTC approach.
Roger Song, Analyst — Jefferies
Yeah. Good. Thank you. And then on the side effects part, you have some headache percentage. So can you just describe the nature of that cluster after the dose, And then how do you think about if you redose them and then how the AE profile is going to look like?
Carl Hansen, CEO
Yeah, so there was an enrichment in headaches, both in the phase one and the phase two. I think roughly twice as many headaches in the active group as the control group. These were generally mild, and they were self-resolving with a median period of about a day. So mild means that, you know, patients didn't even take an Advil or a Tylenol to treat it. So we think it's a very favorable safety profile. And honestly, if you're going to get some kind of adverse event, this is sort of the one that you want. You did mention, and I think it's correct, though I haven't really analyzed the data, that most of those events tend to happen quite early in treatment. So if that is the case, then what we'd expect is on the second dosing, we don't see the same enrichment as we did in the beginning. That would be great. The headaches are not a problem. They were not reported by the physicians doing the trial. But, of course, if it's a headache when you first begin the drug and then it doesn't happen again, And you're treating people for, you know, potentially years, because the median time of VMS with menopause is about seven years. It's a non-factor. And I think given the severity of headaches, it's already a non-factor, but something will get a better line of sight on after the OLE data. Got it.
Roger Song, Analyst — Jefferies
Okay. And at the data release, how much the regulatory update you will give us, and then particularly around, you know, phase three design, and then a little bit more specifics. Oh, that's a little bit waiting for the end of phase two meeting for giving us.
Carl Hansen, CEO
That's great. So we've started engaging with regulators already, but of course, you know, when the full trial is done, we'll have, you know, post-phase meetings with the FDA, with the EMA, and other jurisdictions. Once we have alignment on the development plan, then I suspect we'll have, you know, either an earnings call or a separate event where we lay out, you know, here's the plan forward, here's the patient population, here's the design. And that will lay out both our, you know, registrational studies for VMS with menopause and also some studies that we'll be doing in parallel for the treatment of hot flashes associated with hormone deprivation in both prostate cancer and in breast cancer. So we see that as an important event and one that we definitely want to make sure that we have full disclosure and transparency with investors.
Roger Song, Analyst — Jefferies
Got it. And then, you know, you have a phase two data, and then talk with the FDA, start the phase three. Anything else you need to do before you can start phase three, before the unported? Because I believe this trial is running in Canada, so how much kind of bridging study, you know, or PK you need to do?
Carl Hansen, CEO
Yeah, so the rate-limiting steps to starting the registrational study, which I think would start somewhere mid-ish next year, we're not giving better guidance than that, is regulatory alignment and then the CMC. So we're intending to do the trials either with pre-filled syringe or with an auto-injector, and so we're getting that CMC up and running. That has had to move quickly. I'll just remind people that a year and a half ago, this was still a preclinical asset, so it's moved very quickly through trials, and we're trying to catch the CMC up with this and move as quickly as possible. In terms of where the trials were done, all of the trials were done in Canada, So we managed to recruit, you know, 92 patients in the Phase 2 in about six months with less than a dozen sites. The recruitment has been very fast. I think that speaks to the unmet need and the number of patients that are out there. That has all been done, you know, in complete alignment with what would be the standards of the FDA. So we're not anticipating any friction in transferring that to an IND to the FDA and getting things started in the U.S. as well. Got it.
Roger Song, Analyst — Jefferies
And then on the CMC part, you know, either pre-filled syringe or auto-injection, and how much more work you're, you know, anticipating than just confirming this is a one shot, you know, one dose for the 300-millimeter web?
Carl Hansen, CEO
Yeah, so either the pre-filled syringe or the auto-injector can easily accommodate a two-milliliter volume. We're already formulated with stability at 150 mg per ml, and given the four-week data, we know that that's sufficient. So we don't think there's any significant CMC or formulation work to be done. It's really just about getting the devices ready and getting the CMC in a format that's suitable for commercialization so we can get forward with the phase three.
Roger Song, Analyst — Jefferies
Okay, it's a 150 milligram one shot, and you have two shots for the mask?
Carl Hansen, CEO
So it's formulated at 150 mg per mil, and you can have two mil in the shot, so it's 300 milligrams. Sorry if I misspoke on that. No worries. Just to confirm that.
Roger Song, Analyst — Jefferies
Okay, and then the other thing is, I think on the earning call, you also talk about the potential head-to-head comparator, active comparator, understanding you don't necessarily go against the orals, but also maybe help the pricing talk and then anything else. Just what's the latest thinking about that? And then if you don't do that, and how do you think about the access and the pricing you can do? Because right now, the standard care is about $5,000.
Carl Hansen, CEO
So, complicated questions. So, we are thinking a lot about that. We don't have, you know, precise or definitive guidance, but I'll just sort of share our thinking. Right now, for the registrational studies in menopause, we're expecting a placebo-controlled study, and probably, you know, pretty vanilla that would reflect, you know, closely what has been done with the two small molecules, Vioza and Lindquit. So around 1,500 patients, two different trials, the endpoints that have been used, which is frequency and severity at four weeks and 12 weeks, followed by an extension period for safety. It is interesting to consider, and we definitely are considering, some head-to-head studies. There is some complexity in implementing that, which I think make it not appropriate or necessary for the registrational study. And there's also an open question as to what would be the right comparator. So right now there is, you know, Linquid and Bios are the two NK3R antagonists, small molecules. And, you know, currently based on ACOG guidance, they're, you know, perhaps not even, but on a similar playing field to some other non-hormonal treatments like SSRIs or SNRIs. And gabapentin is used a little bit as well. So one option might be a trial where you said, you know, it's ABCL635 against physician choice. That's something that would not be part of the regulatory package, but that we've done alongside of that. And from the pricing side, You know, if the data holds as it is, and we believe it will, but of course, you know, you can't count your chickens, I think there's a strong case for improved pricing versus the small molecules. You have much better efficacy, better safety, better convenience, and, you know, I wouldn't try to preempt that discussion except to say that in addition to, you know, that commercial model, There's another model that might be direct to patients, and there the pricing pressure is more about consumer pricing than it is about reimbursement. And so we'll think about both of those.
Analyst
One thing about the orals that are already on the market, have you looked at what your expected IP lives for them may be? How many years you may have a branded market still available for any generic competitors they start to enter?
Carl Hansen, CEO
It's a good question. I have looked at that. I don't have it off the top of my head. They still have considerable patent coverage. From where we are today, I don't think it's that relevant anymore because the efficacy is so much better than the small molecules. Although we go after the same target, we don't consider that to be close competition, and we think this product is going to stand on its own. Our product has just under 20 years of patent life, so we're still very early in the process here.
Roger Song, Analyst — Jefferies
In the beginning, maybe that's relevant because you're targeting comparable efficacy. Now you're just too far superior, so it's no longer...
Carl Hansen, CEO
I think that's exactly right. Okay, got it.
Roger Song, Analyst — Jefferies
And then in terms of the, you know, you're obviously not showing any liver signal, and then for the orals, they do have that monitoring requirement and then even the AE warning in the label. So how likely this will be a class kind of situation versus you, you know, just as a different compound, you're not going to have any language in the label?
Carl Hansen, CEO
Yeah, well, there's always a question as to how it's perceived by regulators. Which I wouldn't, you know, dare to guess at, but from a scientific perspective, we think it's very clear that the liver signal that's seen with the small molecules has to do with metabolism of the small molecules. And, in fact, one of the core, you know, pillars of the program when we began was that an antibody should not have that effect. So antibodies are obviously not small molecules. They're metabolizing your liver, and we don't think that there's any on-target effect that's associated with that. It's up to us to prove that, but the early data we have shows that there's no sign of liver toxicity or elevated liver enzymes, and we expect that to hold going forward.
Roger Song, Analyst — Jefferies
Okay. All right. So you mentioned you have cancer-related, the middle-modal syndrome, the cancer-related, the VMS. So I know the breast cancer, maybe the path was a little bit more clear, and then prostate is less so. So just what's the timeline look like, and then what do you want to achieve there?
Carl Hansen, CEO
Yeah. So in addition to – it's actually – it's a market I think we don't say enough about Because we're so, so much of the attention is on hot flashes secondary to menopause that people, I think, overlook the size of the opportunity on oncology. There's really quite a large patient population, even in just the U.S., in breast cancer and in prostate cancer. In both of those, you know, hormone deprivation is one of the key therapies. Hormone deprivation drives a menopausal state or a similar state in men that results in the same physiology and the same hot flash responses. Um, so, uh, Linquit, which is the, uh, the Bayer molecule has done a trial, uh, in hot flashes in breast cancer, uh, that was very successful. I think it gives a lot of confidence that the biology translates the way that you think it would, and also has laid out, you know, what would be reasonable, uh, patient inclusion criteria and effect size, uh, that could be expected. So that's a study where we think we could probably go, you know, towards late-stage studies more quickly than in prostate cancer, where there has been some off-label use, but a study like that has not been done. So on the prostate cancer side, it may require something more like a phase two that then moves it towards a phase three.
Roger Song, Analyst — Jefferies
Got it. And obviously, you are full speed ahead into the pivotal design and then running the trial. And then how should we think about the corporate strategy related to the partnership and then when or if you need someone either in the U.S. or ex-U.S.?
Carl Hansen, CEO
Sure. So in terms of late-stage development, we are fully committed and moving full force to build up the team and get that going. So we're certainly not looking for a partner for late-stage development. On the commercialization side, I think it's interesting. As I mentioned, this is a product that I think uniquely fits into an online telehealth, more direct-to-consumer type model, which is quite compelling for a young biotech. So we're looking at that quite seriously. That could perhaps be done solo. It could perhaps be done with the right partnership. We haven't decided that yet, but we're currently moving as though we have to act on our own, and then we're going to respond to opportunities as they come. Awesome.
Roger Song, Analyst — Jefferies
You mentioned earlier you have a Half-Life extended version 992. So beyond the Half-Life extension, any other benefit in terms of potency, maybe some other benefit you're going to see compared to the 365, And then maybe can expand the indication or to, you know, address a broader population for the half-lash.
Carl Hansen, CEO
Yeah, so ABCL635 is a terrific molecule. I probably should have said more about that. So this is an antibody against a GPCR target. It has to be developable. It has to be very potent. You need complete inhibition to get the effect that you want. That's in a class of antibody discovery that few companies could do well. 992 is an analog of that. So it's closely related to it. As I mentioned, it is engineered to have, you know, extended half-life, but we expect that the biology that we're seeing in 635 that looks so good will translate directly to 992. So really, we've got a product that is just more convenient, easier to make, and, you know, helps to create an even better product on top of 635. I will add that the development of 992 is no indication that we're backing away from 635. We see that this is a blockbuster product that we're all in for, and I think once 992 moves forward, it also creates some interesting opportunities commercially to decide how to position both those products.
Roger Song, Analyst — Jefferies
Okay. At this point, you're committed to move forward both, and then obviously 365, you can move into The approval, and then when you have a 992 upcoming, and then you will think both products will coexist, or something will happen, kind of a life cycle management?
Carl Hansen, CEO
I mean... To be determined, today I'd say I think that they would coexist, and it's sort of, it's interesting from a pricing perspective. You know, one of the things we're definitely, I should have probably said this before, one of the things we're definitely attuned to is that these days the world's competitive, and when you have breakthrough data like this, you expect that there will be companies standing up and trying to make a half-life extended version of the same thing. Now we've got a molecule that's well ahead. We've also been very aggressive on the intellectual property side. So, you know, in the conceivable space that is near this antibody, we think we've got good protection. We want to make sure that because we did the hard work and we got the great data, that we get the full benefit of that as we move it forward. And I think that's going to be 992 and 635 in parallel.
Roger Song, Analyst — Jefferies
Yeah, that's a very sound strategy. Just lastly, you do have this antibody discovery and an engineering platform. You have a couple other earlier pipelines without even telling us the target. Okay, so how far away for you to advance them, and then what are the, you know, financing situation can support all of them?
Carl Hansen, CEO
That's a great question. You know, since the data, 99% of conversations about ABCL 635, there is a much bigger company here. So we have a robust platform and a very exciting pipeline coming forward. So the first two programs behind 635 are ABCL 688 and 386, which are both in IND enabling activities that could be on deck to be in the clinic next year. And just on the last call, we released two more, ABCL 385, which is an undisclosed program in oncology, and ABCL 646, which is a first-in-class antibody antagonist against a GPCR, pardon me, against an ion channel target. That's what I'm excited about. I think it'll be a good example that shows the world that the platform can solve problems that have been completely out of reach for most programs for most platforms for many years. And as it stands, we currently have about $900 million in liquidity, perhaps even more because we own our real estate. And so we're fully loaded to lean into 635 and 992 and continue to push the other programs forward. And our objective in the long run is to repeatedly show that we can invent, develop, and commercialize breakthrough medicines for patients in a variety of different indications. So ABCL635's first example, we hope to follow that up with more.
Roger Song, Analyst — Jefferies
Excellent. Thank you, everyone. Thank you, Karl.